Related Experiment Video
Updated: Mar 22, 2026
07:03
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
2.0K
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
Swaytha Ganesh1, Vinod K Rustgi2
1Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Presbyterian, M2, C-Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Clinics in Liver Disease
|April 12, 2016
Summary
Lifestyle changes like weight loss and exercise improve nonalcoholic steatohepatitis (NASH). While promising drugs exist, a combination approach is best, but no single treatment works for everyone. Further research is essential.
Area of Science:
- Hepatology
- Metabolic Disorders
- Gastroenterology
Background:
- Nonalcoholic steatohepatitis (NASH) is a progressive liver disease characterized by fat accumulation, inflammation, and liver cell damage.
- Biochemical and histologic abnormalities in NASH can be improved through lifestyle interventions.
- Emerging therapies target underlying mechanisms such as insulin resistance, oxidative stress, and fibrosis.
Purpose of the Study:
- To review current and potential therapeutic strategies for nonalcoholic fatty liver disease (NAFLD) and NASH.
- To evaluate the efficacy and limitations of various treatment modalities.
- To highlight the need for a comprehensive approach to NASH management.
Main Methods:
- Review of existing clinical and preclinical studies on NASH treatments.
- Analysis of the impact of lifestyle modifications (weight loss, exercise, diet).
- Evaluation of pharmacotherapies targeting specific pathways like insulin resistance and oxidative stress.
Main Results:
- Weight loss, exercise, and diet modification show significant improvements in NASH.
- Insulin sensitizers and vitamin E are promising but associated with side effects.
- A combination of lifestyle changes and pharmacotherapy may be beneficial.
- No single treatment is universally effective for all NASH patients.
Conclusions:
- A multifaceted approach combining lifestyle changes, weight loss, and pharmacotherapy is recommended for NASH.
- Current treatments have limitations, and no universally applicable approach exists.
- Continued research into novel drugs and therapeutic strategies is crucial for advancing NASH treatment.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Atherosclerosis III: Management
573
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
573
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
254
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
254
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
274
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
274
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K